Surgical and systemic management of endometrial cancer: an international survey
- 15 October 2014
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 291 (4) , 897-905
Abstract
Purpose To ascertain the spectrum of clinical management of endometrial carcinoma (EC) the largest international survey was conducted to evaluate and identify differences worldwide. Methods After validation of a 15-item questionnaire regarding surgical and adjuvant treatment of EC in Germany, an English-adapted questionnaire was put online and posted to all the major gynecological cancer Societies worldwide for further distribution commencing in 2010 and continued for 26 months. Results A total of 618 Institutions around the world participated: Central Europe (CE), Southern Europe (SE), Northern Europe (NE), Asia and USA/Canada/UK. Both a therapeutic and staging value was attributed to systematic pelvic and paraaortic lymph node dissection (LND) in CE (74.6 %) and in Asia (67.2 %), as opposed to USA/UK where LND was mainly for staging purposes (53.5 %; p < 0.001). LND was performed up to the renal veins in CE in 86.8 %, in Asia in 80.8 %, in USA/UK in 51.2 % and in SE in 45.1 % (p < 0.001) of cases. In advanced disease, centers from Asia were treated most with adjuvant chemotherapy alone (93.6 %), as opposed to centers in SE, CE and UK/USA that employed combination chemo-radiotherapy in 90.9 % (p < 0.001) of cases. Paclitaxel/carboplatin was mostly used followed by doxorubicin/cisplatin (75 vs. 23.3 %; p < 0.001). In total, 94 % of all participants supported the concept of treating EC patients within appropriate clinical trials. Conclusions There is broad range in both the surgical and adjuvant treatment of EC across different countries. Large-scale multicenter prospective trials are warranted to establish consistent, evidence-based guidelines to optimize treatment worldwide.Keywords
This publication has 32 references indexed in Scilit:
- Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancerGynecologic Oncology, 2012
- Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?Gynecologic Oncology, 2012
- The impact of surgical guidelines and periodic quality assessment on the staging of endometrial cancerGynecologic Oncology, 2011
- The Role of Radiotherapy in Endometrial Cancer: Current Evidence and TrendsCurrent Oncology Reports, 2011
- Endometrial Cancer State of the Science MeetingInternational Journal of Gynecological Cancer, 2009
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Lymphadenectomy's Role in Early Endometrial Cancer: Prognostic or Therapeutic?JNCI: Journal of the National Cancer Institute, 2008
- Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical stagingGynecologic Oncology, 2008
- A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with “high-risk” endometrial cancerGynecologic Oncology, 2005
- Routes of Lymphatic Spread: A Study of 112 Consecutive Patients with Endometrial CancerGynecologic Oncology, 2001